DNX and XL-protein Announce Collaboration to Develop Novel, Long-Acting Biopharmaceutical Products

New Half-Life Extension Platform Technology Will Support the Development and Commercialization of Novel Therapeutic Proteins Addressing Unmet Needs in Immunology, Metabolism and Ophthalmology

Irvine, CA and Freising, Germany, June 30, 2015 — DNX Biopharmaceuticals, Inc. (“DNX”) a company with a team of experienced industry professionals with a long and successful track record of developing and manufacturing biopharmaceutical products, and XL-protein GmbH (“XLp”), a leader in protein engineering and modification technologies, today announced a collaboration for the development and commercialization of novel, long-acting biopharmaceutical products. Under this strategic collaboration, XLp will contribute its half-life extension platform technology (PASylation®) and certain molecules that have completed in vivo efficacy proof-of-concept and preclinical studies, and DNX will add its pipeline of candidate molecules for development and commercialization to address a range of unmet needs in Immunology, Metabolism and Ophthalmology. Financial terms have not been disclosed.

Half-life extension is a critical aspect of developing a successful protein pharmaceutical, as not all efficacious payloads have natural half-lives that are amenable to reasonable dosing intervals or regimens. The novel PASylation platform is designed to offer improved half-life, pharmacokinetics, pharmacodynamics, bioavailability, solubility and overall enhanced patient compliance and safety. PASylation is a highly tunable technology and offers a paradigm shift in patient care and better compliance in multiple therapeutic areas to improve the quality of life for millions of patients.

“We are pleased to be partnering with XL-protein on the development of new molecules specifically designed to improving the lives of patients, while simultaneously helping to alleviate the clinical burden,” said Dr. Rajiv Datar, Chief Executive of DNX. “By combining DNX’s 250+ person-years of experience of biologics process development, clinical development and GMP manufacturing expertise with XLp’s revolutionary PASylation platform, we hope to ‘Make Good Drugs Great,’ and to delivering more gain and less pain to patients.”

“Working with DNX to create a range of novel long-acting biopharmaceuticals that will provide benefits to patients and to the healthcare services by reducing clinical burden is exciting and satisfying,” said Claus Schalper, Managing Director of XL-protein. “Our team shares a common passion with DNX to ‘Making Good Drugs Even Greater’ by contributing our half-life extension / drug delivery technology to support successful product development and commercialization.”

About DNX
DNX is a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of patients with life-long diseases. Headquartered in Irvine, CA, USA, DNX is pursuing the development of new therapeutic proteins utilizing 21st century, half-life extension-based drug delivery technologies.
www.dnxbio.com

About XL-protein
XL-protein is a German biotech company commercializing the ground-breaking PASylation technology, which enables the design of biopharmaceuticals with extended plasma half-life and enhanced action. With its strong proprietary technology position XL-protein focuses at the preclinical as well as clinical development of PASylated proteins in various disease areas. The company is located at Freising, Germany, in the neighborhoods of Munich International Airport and the Technical University of Munich.
www.xl-protein.com

XL-protein GmbH
Lise-Meitner-Str. 30
85354 Freising
Germany

Press contact:
Uli Binder, CTO, XL-protein GmbH, +49 8161 53730 90, bd@xl-protein.com

This release was published on openPR.